REGN Regeneron Pharmaceuticals, Inc. featured news, full reports, and detailed charts
Regeneron Pharmaceuticals, Inc. (REGN) Wrap Up:
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron Pharmaceuticals, Inc., and actual events or results may differ materially. These statements concern, among other things, the possible success and therapeutic applications of our product candidates and research programs, the timing and nature of the clinical and research programs now underway or planned, and the future sources and uses of capital and our financial needs. These statements are made by us based on management’s current beliefs and judgment. In evaluating such statements, stockholders and potential investors should specifically consider the various factors identified under the caption “Risk Factors” which could cause actual results to differ materially from those indicated by such forward-looking statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f27%2f0000950123-08-002191.html#FIS_BUSINESS"Regeneron Pharmaceuticals Inc. (REGN:NASDAQ)
Snapshot of Regeneron Pharmaceuticals Inc. (REGN)
|
OPEN
$18.49
|
PREVIOUS CLOSE
$18.67
|
|
|
DAY HIGH
$18.79
|
DAY LOW
$18.25
|
|
|
52 WEEK HIGH
09/1/09 - $23.49
|
52 WEEK LOW
03/12/09 - $11.81
|
|
|
MARKET CAP
1.5B
|
AVERAGE VOLUME 3 mo
959.9K
|
|
|
DILUTED EPS TTM
$-0.79
|
SHARES OUTSTANDING
80.5M
|
|
|
REGN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
REGN Top Compensated Officers
Executives, Board Directors
Key developments for Regeneron Pharmaceuticals Inc. (REGN)
To discuss the company's expanded strategic antibody collaboration with sanofi-aventis
Sanofi-Aventis and Regeneron Pharmaceuticals Inc. announced that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. Sanofi will increase its annual funding commitment from $100 million to $160 million beginning in 2010, and the research funding will now extend through 2017. The companies aim to advance an average of four to five antibodies into clinical development each year. In addition to its VelocImmune() technology, Regeneron will contribute to the collaboration its next generation technologies related to antibody generation. Sanofi-aventis has an option to extend the discovery program for up to an additional three years for further antibody development and preclinical activities. The amendments announced do not change the financial terms of the November 2007 agreement governing the development and commercialization of antibody drug candidates arising from the discovery collaboration. To date, Regeneron and sanofi have advanced four therapeutic antibodies into clinical development and have filed an IND for a fifth additional antibody. Among the four antibodies in clinical development, three are antibodies to (1) the Interleukin-6 receptor (IL-6R), being developed for the treatment of rheumatoid arthritis, (2) Nerve Growth Factor, being developed for the treatment of pain, and (3) Delta-like Ligand 4 (Dll4), being developed for the treatment of advanced malignancies. The targets of the two other antibodies have not been disclosed.
Regeneron Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenue of $117,455,000, loss from operations of $1,291,000, net loss before income tax of $1,015,000, net loss of $1,015,000 or $0.01 basic and diluted per share compared with revenue of $65,584,000, loss from operations of $17,900,000, net loss before income tax of $16,005,000, net loss of $19,084,000 or $0.24 basic and diluted per share over the same period last year. For the nine months, the company reported revenue of $282,468,000, loss from operations of $34,695,000, net loss before income tax of $31,341,000, net loss of $31,341,000 or $0.39 basic and diluted per share compared with revenue of $182,620,000, loss from operations of $53,659,000, net loss before income tax of $46,541,000, net loss of $49,620,000 or $0.63 basic and diluted per share over the same period last year.
REGN Competitors
| Company | Last | Change |
| Celera Group | $6.25 USD | -0.05 |
| Crucell NV | €14.46 EUR | +0.085 |
| OSI Pharmaceuticals Inc | $32.79 USD | -0.07 |
| Pfizer Inc | $18.36 USD | +0.25 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | REGN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.4x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.1x |
|
|
REGN |
||
REGN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Regeneron Pharmaceuticals, Inc.
More news for REGN
Sanofi-Aventis, Regeneron extend development deal
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
Sanofi Expands Regeneron Deal
By RON WINSLOW Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA said they are expanding their drug development partnership under terms in which the French drug maker will invest more than $1 billion for research at the biotechnology company over the next eight years. Under the agreement, Sanofi will pay Tarrytown, N.Y.-based Regeneron $160 million each year beginning next year and extending through 2017 to co-develop new antibody drug candidates. Most of the money isn't subject to reaching specific research or marketing milestones. They will share in the profits of any drugs that reach the market. Under a collaboration begun in 2007, the two companies have put four compounds into early stage human studies and are awaiting approval on a fifth candidate. Sanofi was contributing $100 million annually through 2012 under that pact, which is being expanded under the new agreement. Sanofi owns a nearly 20% stake in Regeneron, but under a standstill agreement can't acquire more than 30% of the company. It didn't increase its stake with the new pact. Leonard S. Schleifer, Regeneron's president and chief executive officer, said that under the partnership his company heads up management of the research and discovery enterprise, anchored by a special technology to develop antibodies. Sanofi would take the lead on commercial development of compounds the companies advance beyond initial human studies. Sanofi is supporting the research "without taking over the culture and changing the company—without Sanofizing us," Dr. Schleifer said. The approach reflects Sanofi Chief Executive Officer Christopher Viehbacher's views that th...Click here to read the whole Article (external link)
Regeneron, Sanofi-Aventis to Continue Collaboration
Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business Advertise with us | Jobs at FOX Business Network | Internships at FBN Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com. Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions. This material may not be published, broadcast, rewritten, or redistributed. ©2009 FOX News Network, LLC. All rights reserved. ...Click here to read the whole Article (external link)
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
Item 1.01. Entry Into a Material Definitive Agreement. Amended and Restated Collaboration Agreements On November 28, 2007, Regeneron Pharmaceuticals, Inc. (the "Company") entered into a global, strategic collaboration with various affiliates of sanofi-aventis, a company organized under the laws of France (sanofi-aventis and its affiliates are referred to herein as "Sanofi"), to discover, develop and commercialize fully-human therapeutic antibodies utilizing the Company's VelociSuite of technologies (the "Collaboration"). The Collaboration has been governed by a Discovery and Preclinical Agreement, dated November 28, 2007 (the "Discovery Agreement"), by and between Aventis Pharmaceuticals Inc. and the Company, and a License and Collaboration Agreement, dated November 28, 2007, by and among Aventis Pharmaceuticals Inc., sanofi-aventis Amérique du Nord and the Company (the "License and Collaboration Agreement" and, together with the Discovery Agreement, the "Original Collaboration Agreements"). On November 10, 2009, the Company and Sanofi amended the Original Collaboration Agreements by entering into an Amended and Restated Discovery and Preclinical Agreement (the "Amended and Restated Discovery Agreement") and an Amended and Restated License and Collaboration Agreement (the "Amended and Restated License Agreement"). The material amendments to the Original Collaboration Agreements are as follows: (i) the funded program for Regeneron to identify and validate potential drug discovery targets and develop fully-human therapeutic antibodies against such targets (the "Discovery Program") was extended by an additional five years to end on December 31, 2017, subject to an option for Sanofi to extend certain antibody development and preclinical activities under the Discovery Program for up to three additional years; (ii) the maximum annual amount reimbursed by Sanofi under the Discovery...Click here to read the whole Article (external link)